Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Deferred Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Current Deferred Revenue for 16 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue fell 79.14% to $2.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Sep 2025, down 79.14% year-over-year, with the annual reading at $8.0 million for FY2024, 56.52% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $2.9 million at Dexcom, down from $6.1 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $18.4 million in Q4 2023, with the low at $1.8 million in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $7.5 million, with a median of $7.8 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue skyrocketed 380.95% in 2022, then tumbled 79.14% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $2.1 million in 2021, then surged by 380.95% to $10.1 million in 2022, then surged by 82.18% to $18.4 million in 2023, then plummeted by 56.52% to $8.0 million in 2024, then crashed by 63.75% to $2.9 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.9 million, $6.1 million, and $7.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.